FibroBiologics closed at $0.99 on Nov 3, up 7.60%, 98.7% below its 52-week closing high. Volume of 41.9K shares was 0.34× its 20-day average (below normal).
Split-adjusted performance: -16.1% over one month, -25.6% over six months, -87.4% over one year.
Short interest was 330.6K shares at the Oct 15 settlement, down 36.7% from the prior report (6.0% of float, 2.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| FBLGFibroBiologics | $0.9900 | +7.60% | −25.6% | — | — | — | $7.0M | |
| ALZNAlzamend Neuro | $1.46 | +16.80% | +36.4% | — | — | — | $7.0M | Compare |
| ENVBEnveric Biosciences | $1.50 | +3.45% | −56.9% | — | — | — | $6.7M | Compare |
| ENSCEnsysce Biosciences | $0.3777 | −1.15% | −5.6% | −15.1% | −220.8% | — | $7.3M | Compare |
| CNSPCNS Pharmaceuticals | $4.55 | +3.64% | −36.4% | — | — | — | $6.6M | Compare |
| NAIINatural Alternatives International | $1.06 | −0.93% | −59.4% | +1.9% | −39.2% | — | $6.6M | Compare |
| XCURExicure | $1.01 | −0.98% | −70.3% | — | — | — | $6.6M | Compare |
| VTGNVistagen Therapeutics | $0.1680 | +0.30% | −72.0% | +504.9% | −882.8% | — | $7.5M | Compare |
| APREAprea Therapeutics | $0.5150 | +4.89% | −38.9% | −100.0% | — | — | $6.5M | Compare |
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
